Category Archives: Alternative Medicine

WEED Australia Ltd. is a majority (>99%) owned subsidiary of WEED, Inc (USA) and one of the first public Cannabis companies in Australia established in March 2017.

TUCSON, AZ / ACCESSWIRE / May 3, 2022 / WEED, Inc. (OTCQB:BUDZ) ("WEED" or the "Company") a global cannabis & hemp bioresearch company based in the USA, focused on the development and application of cannabis-derived compounds for the treatment of human and animal diseases, announced today that its subsidiary, WEED Australia Ltd. completed its financial statement requirements under ASIC RULES and intends to move forward with a formal public offering for WEED Australia later in 2022 or 2023 depending on market conditions. As a current reporting public company in Australia., (all financial statements have been prepared in accordance with The Corporations Act of 2001 and Australian Accounting Standards and interpretations of the Australian Accounting Standards Board.) WEED is currently looking for and talking to candidates to form strategic partnerships to join under its WEED umbrella.

Glenn E. Martin, WEED, Inc.'s Chief Executive Officer, will be traveling to WEED Australia's Gold Coast based headquarters in mid May 2022 to attend the exclusive "United in Compassion" conference May 20th to May 23rd. For more information on the conference please visit UnitedinCompassion.com.au

"WEED Australia looks to continue its R & D in clinical trials domestically as well as in Israel in conjunction with sister company, WEED Israel Cannabis Ltd. on product development and educational tools for doctors, health practitioners and the public. The Cannabis Institute of Australia, WEED Australia's non-profit arm will lead the charge" states Glenn E. Martin , "Our goal is to take care of the domestic Australian marketplace first, with both pharma and non pharma products to deepen knowledge and uses of Cannabis and its derivative forms from high THC to CBD & CBG compounds. Research is key to long term success. An informed customer is your best patient." Martin continues; "We believe the majority of discoveries in Cannabis and Hemp are yet to be found. These are exciting times that will change global health worldwide!

WEED, Inc.'s Subsidiaries past comments from 2021/2022

Story continues

WEED Israel (Cannabis) Ltd. "After over 2 years of putting human clinical trials and product development on hold due to COVID, WEED Israel is poised and anxious to build out our global brands in both pharmaceutical and non-pharmaceutical categories, starting with women's health and veterans' ailments (PTSD) to healthy green alternative medicines" stated Elliot Kwestel, Managing Director of WEED Israel (Cannabis) Ltd. based outside Jerusalem. Kwestel further commented, "WEED Israel looks to enrich and expand our clinical trials with both THC and Cannabinoid studies to promote healthy living for generations to come."

WEED Australia Ltd. and The Cannabis Institute of Australia (C.I.A.), our Australian non-profit arm, based in Queensland on the Gold Coast. Managing Director Patrick Brodnik stated, "With the new rules out governing cannabis & hemp in Australia and the announcement on 1st of February 2021 to allow over-the-counter CBD medicines in pharmacies, timing is perfect to begin our clinical trials in Israel and Australia to bring new curative products to market as we close out COVID mandates this year. Managing Director Brodnik continues, "This year 2022, we believe the future of decriminalizing cannabis and hemp globally will prove to be a giant leap forward for worldwide cannabis legalization."

WEED Hong Kong Ltd. Director Nicole Breen agrees, "The pandemic has affected all of us on a worldwide basis. Healing our planet with natural therapies, treatments and eventual "cures" utilizing natures' own Cannabaceae plant with its many properties, both with high tetrahydrocannabinol (THC) and cannabidiol (CBD) compounds, I believe will change the force of medicine forever in the years to come. We look forward to an exciting year end and a Prosperous 2022."

Caution Regarding Cannabis Operations in the United States

Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. While legal in certain states, cannabis remains a Schedule I drug under the U.S. Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute or possess cannabis. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable U.S. federal money laundering legislation. Investors should carefully read the risk factors and disclosures contained in our offering circular before making any decision to invest in our company.

Forward Looking Information

This news release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions, and include statements with respect to future revenue and profits. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Legal Notice

The information is provided for convenience only, is not investment advice and may not be relied upon in considering an investment in WEED, Inc. No representation or warranty, express or implied, is made as to the accuracy or completeness of any information contained herein, and any investment decision should be based solely on the information contained in the offering circular and related materials, and the investors independent research. No representation or warranty, express or implied, is made as to the future performance of any investment in WEED, Inc. or that investors will or are likely to achieve favorable results, will make any profit at all or will be able to avoid incurring a loss on their investment. In addition, prospective investors are encouraged to consult with their financial, tax, accounting or other advisors to determine whether an investment in WEED, Inc. is suitable for them.

Media Contact:Glenn E. Martin, CEO1-520-818-8582Glenn@WEEDincUSA.com

SOURCE: WEED, Inc.

View source version on accesswire.com: https://www.accesswire.com/699770/WEED-Australia-Ltd-a-Public-Company-and-Fully-Reporting-Under-Australian-Securities-and-Investment-Commission-ASIC-Rules-Completes-Five-Full-Years-of-Audited-Financials

The rest is here:

WEED Australia Ltd., a Public Company and Fully Reporting Under Australian Securities and Investment Commission (ASIC) Rules, Completes Five Full...

UPPER NYACK, N.Y.--(BUSINESS WIRE)--A new review article from CreakyJoints, the international digital community for millions of arthritis patients and caregivers who seek education, support, advocacy, and patient-centered research, finds that there has been limited progress in understanding the potential of cannabis based therapies for the treatment of pain associated with rheumatic conditions in the past five years because of a lack of standardization of clinical research and barriers to conducting research due to existing federal and state regulations. The article, Cannabis for rheumatic disease pain: A review of current literature, published in the latest issue of Current Rheumatology Reports.

The review found that legalization and decriminalization of cannabis at the state level reflects and promotes changing attitudes about cannabis corresponding to its increased use across a broad range of conditions, including rheumatic diseases. In addition, over 90 percent of Americans overall now support legal use of medicinal marijuana. Unfortunately, while there is strong, preclinical (animal) evidence showing that cannabis-based products play a role in alleviating pain and reducing inflammation, the highly variable state and federal statutes have limited patient-centered prospective research, education of clinicians, and comfort of patients in disclosing use of these therapies to their clinicians.

In 2019, CreakyJoints presented data from our ArthritisPower Research Registry study showing more than half of arthritis patients reported wanting information on or actually had tried marijuana and/or cannabidiol products for a purpose they perceived as medical (often for pain relief and help sleeping) and yet, three years later, theres been virtually no advancement in the research necessary to provide clinical evidence that rheumatologists and patients need to make decisions about cannabis use for symptom relief in combination with approved treatments, said W. Benjamin Nowell, PhD, Director, Patient-Centered Research at CreakyJoints, principal investigator of the ArthritisPower Research Registry.

Without this research, it is impossible to develop clinical guidelines for medicinal cannabis in the U.S., which is vital for patients a seeking the full range of treatment options to explore in partnership with their physicians. The best way to treat rheumatic conditions is through the use of U.S. Food and Drug Administration approved medications, which are backed by evidence demonstrating their effectiveness and safety profile, he added.

Only three cannabis-based medications are approved by the U.S. Food and Drug Administration and none of them are for treatment of pain or other symptoms related to rheumatic conditions.

Lack of Research in Arthritis Limits Potential

In the review, researchers explain that many studies have shown that cannabinoids are very effective in the laboratory at decreasing inflammation in cells and reducing both inflammation and pain in mice and rats. In addition, studies in humans that support efficacy are primarily surveys of people using medicinal marijuana who report relief of pain. In rheumatic diseases, there are very few studies of cannabis-based therapies in humans and the clinical trials conducted to date have very small sample sizes and inconsistent methods.

Although the clinical evidence about cannabis for rheumatic disease pain is lacking, it is nevertheless important to educate patients about the known benefits and risks of alternative treatments, including medical cannabis. As a rheumatologist who treats patients with pain, I am aware that some of my patients have found cannabis to be an effective option when traditional medications fail to reduce their pain, said Dr. Stuart Silverman, MD, FACP, FACR, rheumatologist, Clinical Professor of Medicine, Cedars-Sinai Medical Center and UCLA School of Medicine and Medical Director, OMC Clinical Research Center, Beverly Hills, CA. I am open to discussing medical cannabis when patients express an interest in its use. Then, if they choose to use it, I follow them closely to monitor efficacy and any side effects and to ensure that they do not consider it as a replacement for FDA-approved disease-modifying drugs.

CreakyJoints recommends that rheumatologists and healthcare providers be prepared to discuss medicinal cannabis with their patients in an empathetic, nonbiased manner. Suggestions include:

About ArthritisPower

Created by CreakyJoints, ArthritisPower is the first-ever patient-centered research registry for joint, bone, and inflammatory skin conditions, as well as arthritis and rheumatologic manifestations of gastrointestinal-tract (GI) and skin conditions. With tens of thousands of consented arthritis patients, the free ArthritisPower mobile and desktop application allows patients to track their disease and participate in voluntary research studies in a secure and accessible manner. Results from ArthritisPower studies are frequently published in peer-reviewed journals and presented at medical meetings in the United States and around the world. ArthritisPower Patient Governors serve as gatekeepers for researchers who seek to access registry data or solicit the community to participate in unique, voluntary studies. To learn more and join ArthritisPower, visit ArthritisPower.org or, in Spanish, ArthritisPower.org.es.

About CreakyJoints

CreakyJoints is an international digital community for millions of arthritis patients and caregivers who seek education, support, advocacy, and patient-centered research. We represent patients in English, Spanish, and French through our popular social media channels, our websites, and the 50-State Network, which includes more than 1,700 trained volunteer patient, caregiver, and provider health care activists.

Part of the Global Healthy Living Foundation, CreakyJoints also has a patient-reported outcomes registry called ArthritisPower (ArthritisPower.org), which includes tens of thousands of consented arthritis patients who track their disease while volunteering to participate in longitudinal and observational peer-reviewed research. In addition to online and downloadable educational resources, CreakyJoints publishes many arthritis and chronic disease podcast series, available on all major streaming platforms, that provide both patient and provider perspectives. It also hosts PainSpot (PainSpot.org), a digital risk-assessment tool for musculoskeletal conditions and injuries, and eRheum (eRheum.org), for telehealth and virtual-care support. All programming is free, always. For more information, visit CreakyJoints.org.

Find us online:CreakyJoints: CreakyJoints.org CreakyJoints Espaol: CreakyJoints.org.es CreakyJoints Australia: CreakyJoints.org.au CreakyJoints Canada: CreakyJoints.ca Global Healthy Living Foundation: ghlf.org Facebook: facebook.com/CreakyJoints & facebook.com/GlobalHealthyLivingFoundation Twitter: @GHLForg, @CreakyJoints, #CreakyChatsInstagram: @creaky_joints, @creakyjoints_aus, @creakyjoints_esp TikTok: globalhealthylivingfnd

Link:

CreakyJoints Finds Lack of Research Stymies Uptake of Evidenced Based Prescribing of Medical Marijuana for Pain Associated with Rheumatic Conditions -...

Philadelphia, PA, May 03, 2022 --(PR.com)--Dr. Daphne M. Goldberg, M.D., ABIHM, is a highly respected family physician in the Main Line of Philadelphia, Pennsylvania. Board-certified through the American Board of Family Medicine and the American Board of Integrative Holistic Medicine (ABIHM), she is revered in the Philadelphia area as a patient-centered physician, and she is well-known for her exceptional diagnosis skills and compassionate care. During her family medicine residency at the Hospital University of Pennsylvania, Dr. Goldberg co-founded the Covenant House Health Center, a shelter-based clinic for homeless adolescents. After completing her residency training, Dr. Goldberg worked as faculty at the Department of Family and Community Medicine at the University of Pennsylvania Health System, where she taught courses on Community Oriented Maternity Care and Medical Frontiers in Complementary and Alternative Medicine. She maintained a full family practice that included prenatal care and obstetrics. In 2005, Dr. Goldberg left her full-time faculty position at Penn in order to focus on clinical care. She was one of the first doctors to implement, and quickly grew, a successful retainer-based practice. While building her practice, Dr. Goldberg remained committed to medical education, and has continued to teach and train medical students and physicians.

She has lectured at prominent institutions, including Thomas Jefferson University School of Medicine, Philadelphia College of Osteopathic Medicine, Main Line Health System and Drexel University School of Medicine. Recently, Dr. Goldberg co-founded the Center for Integrative and Functional Medicine at Bryn Mawr Hospital. Dr. Goldberg served three consecutive terms on the Board of The American Board of Integrative Holistic Medicine. She has received numerous awards and accolades throughout her career. Recognized as a Castle Connolly Top Doctor since 2013 and Philadelphia Magazine Top Doctors (2018 2021), she received honorary recognition from Exceptional Women in Medicine (2020, 2021). Dr. Goldberg is also the recipient of the CRC Award for Academic Excellence in Chemistry in 1990, Ciba-Geneva Award for Outstanding Community Service in 1995, Janet M. Glasgow Memorial Achievement Citation of the American Womens Association in 1999, Phila Academy of Family Physicians Memorial Prize for Excellence Study of Family Medicine in 1999, AAFP Award for Excellence in Residency Training in 2002, and Best Clinician Award in 2005. Dr. Goldberg maintains hospital affiliations with Bryn Mawr Hospital and Lankenau Medical Center. Dr. Goldberg also writes, records, and produces music and she loves traveling, hiking, and spending time with her family.

View original post here:

Dr. Daphne Goldberg is Being Honored by the Top 100 Registry, and Due to be Featured on the Front Cover of the 2022 Top 100 Doctors, Q1 Edition -...

Nearly a third of all people use CBD products and tend to prefer non-traditional therapies that are becoming more mainstream such as chiropractic. When considering selling CBD, as you see patients you have a great way to introduce them to CBD therapy and guide them to results that will reduce their pain and bring them back to health as soon as possible.

Cannabidiol is a single component of the cannabis plant widely known to have pain-relieving and other health benefits. It is one of over 80 cannabinoids that help reduce anxiety and inflammation.

The chemicals within the cannabis plants, particularly CBD, stimulate the endocannabinoid system, endogenous lipid-based retrograde neurotransmitters binding to cannabinoid receptors, expressed throughout the central (CB1) and peripheral nervous system (CB2). CBD doesnt appear to bind to these receptors but seems to work by preventing the breakdown of the natural endocannabinoids anandamide (AEA) and 2-arachidonoylglyerol (2-AG).

The cannabis plant contains over 400 cannabinoids, terpenes, flavonoids, lipids, and the most famous cannabinoid: delta-9-tetrahydrocannabinol (THC). Most cannabinoids do not produce as strong or effective an interaction with the endocannabinoid system as CBD, and CBD has no hallucinogenic effect.

The other potent chemical within the cannabis plant is THC, which is the hallucinogenic component and still illegal. Fortunately, strains of the cannabis plant that are commercially and legally farmed for CBD contain low levels of to zero THC.

That doesnt mean all CBD products are pure and free of contamination. Under selected studies, various CBD products were tested for the concentration of CBD and other cannabinoids, including THC. Many products did not contain the CBD listed, with some barely containing 5% of the stated value.

Additionally, when legally selling CBD products, the product must contain less than 0.3% THC. Over half contained levels of THC much higher than this, some going above 10%.

If you are considering using CBD products, or you already are, be sure to obtain the quality control data that is legally required to be available with all products to guarantee the levels of CBD and THC within your product. There could be dangerous drug interactions for many of your patients, as CBD and THC interact with medications for pain, cancer, arthritis, seizures and blood pressure.

CBD is metabolized in the liver by the cytochrome P450 enzymes, specifically the CYP3A4 enzyme. Nearly 60% of clinically-prescribed drugs, including methotrexate, are metabolized by CYP3A4. Metabolism of the drugs could be slowed, possibly leading to a dangerous buildup, particularly in methotrexate used for cancer and rheumatoid arthritis, blood pressure medications and blood thinners.

Despite the potential side effects, many people turn to CBD to reduce the side effects and number of medications they take. Many people who use CBD find a significant reduction in the need for prescription medications for pain, anxiety and other health issues.

You should be aware of the side effects of CBD. Although few and very mild, CBD can affect some people negatively. The most common side effect tends to be drowsiness or decreased alertness. CBD can change your patients appetite, for better or worse. Others experience faster-than-normal digestion that can result in diarrhea. Finally, CBD can result in anxiety, mood swings and erratic behavior in some people.

For any of these side effects, you should monitor your patients closely and document their feelings, digestion and any physical side effect to adjust the dosage or cease use altogether.

Any number of reasons exist why people use CBD. The top reasons include:

Of course, there are plenty of false claims out there, including curative solutions for: weight loss, arthritis, diabetes, kidney disease, liver disease, asthma and breathing disorders (smoking cannabis may help, but causes other health problems), and with autoimmune issues.

But lets not forget potentially the biggest downside of CBD its a palliative therapy in most cases. It may not stop the problem from progressing; instead, it unfortunately may only mask the symptoms. Pain, arthritis, anxiety and other issues often have deeper, systemic origins that CBD does not treat.

Still, given a choice between prescription medication or over-the-counter pain relievers and CBD, many choose CBD.

An estimated 33% of the population already uses CBD, with that number expected to double over the next five years. Some research estimates over half of the population will be using CBD to help control health issues within the next 10 years.

As chiropractors, many balance between what is considered allopathic medicine and that considered alternative medicine. Offering CBD can help increase your patients trust and compliance, while helping to deliver increased results. Many patients prefer to speak to chiropractors and other more holistic-based practitioners about CBD versus their regular medical or traditional doctor, and many trust chiropractors will provide natural and safe solutions over prescription medications.

Fortunately, that puts you in a situation of being seen as an authority and the products you offer and use as higher-quality and worth the price. By using and selling CBD in your practice and educating your patients on safe use, you can help establish your authority and have a potential income stream.

However, you must be very careful so youre not perceived as prescribing CBD or recommending CBD over prescription medications. This is considered illegal in most areas and against most chiropractic association guidelines.

Finding the proper CBD product with the easiest delivery and quality necessary to achieve results can be challenging. Poor-quality products may do nothing for your clients.

Most well-established, reputable companies provide CBD oil as their primary delivery method. Most have documented bioavailability at 20-30% and should indicate that in their materials. Nano-particulate-based oil preparations tend to have a high bioavailability. Established professionals trust CBD oil over other methods and applications.

Capsules and edibles have a wide bioavailability range from 5-20%. And when it comes to edibles, the amount of CBD available can vary within the batch from 0-30%. Edibles include gummies, chewables, food-based snacks (brownies, cookies) and liquid drinks.

Topical application for massage therapy and relaxation can be an integral part of your therapy for your patients. Most CBD topical applications have a 1% bioavailability because of poor transmission to the bloodstream. However, the skin and muscle concentration at the application site is much higher (>50%) and can provide tangible results.

There are multiple other delivery forms, including vapes, sublinguals, injectables and patches. However, these are not recommended, as dosing can vary considerably.

Manufacturers should label how much CBD is present within a product. You should work with your patients to understand a proper dose. A common unit of measurement is a 10-milliliter bottle of oil containing 1,000 mg of CBD. At the recommended starting dosage of 5 mg, you would have 200 doses within the bottle. At 0.5 ml per dose, your client would take one drop to achieve proper dosing (one drop = 0.5 ml).

Properly labeled and tested CBD products will contain the correct amount of CBD and often include cheat sheets for how much to use.

Most medical documentation shows most people tolerate 20 to 1,500 mg of CBD per day well. However, this depends on a persons body weight, illness or condition, individual body chemistry, and previous use. Currently, there is no recommended amount of CBD set for health conditions. The exception is the prescription Epidiolex, used for two specific types of seizures. However, there are some common suggestions found in literature:

Anxiety 300-600 mg/day

Central neuropathic and cancer-related pain A maximum of 30 mg/day

Arthritis and pain A maximum of 30 mg/day or 250 mg applied topically

IBS and gut inflammation 5 mg twice daily

The most important thing about CBD dosing is that it follows the biphasic effect. A certain optimal dosing will react well within the body. If the dosage is too low, the results will not be felt. However, if the dose is too high, the CBD interferes with itself and reduces the effectiveness and relief a person feels.

A person will normally feel the effects of CBD within 5-7 days of taking the dose, as long as daily consistency is maintained.

Providing CBD products for sale within your practice can offer you additional revenue and authority. Choosing the better grade and higher-quality CBD products positions you as someone people can trust.

Fortunately, many quality CBD companies offer training and provide services to help set up a practice, providing educational and marketing materials to sell the product.

Additionally, you can start using and selling CBD within your practice through massage therapy to relax muscles. The proper application of massage therapy combined with CBD can help loosen muscles and tendons before an adjustment and help increase the effectiveness and results your patients feel.

The use of CBD within your practice takes a little bit of effort to get established but can provide additional revenue and health benefits to your patients. A quality company will help you set up and make sales. The pain relief your patients can get from CBD is worth the time and effort you put into it.

ANTHONY CRIFASE, DC, CNS, DACBN, is double board-certified in clinical nutrition and maintains an active virtual functional medicine and chiropractic practice. With experience in multiple different industries and as a seasoned chiropractor who understands the ins and outs of functional medicine, chiropractic and practice management, he is on a mission to help other practitioners maximize their time, revenue and systems. Learn more atdrcrifase.com.

Read the original post:

Selling CBD: 1 out of 3 patients are already using CBD products - Chiropractic Economics

Former world heavyweight champion Mike Tyson has had a profound love for alternative medicine. Recently, podcaster Joe Rogan was seen advising Tyson to ignore medical advice.

ADVERTISEMENT

Article continues below this ad

Tyson was hosting his, Hotboxin with Mike Tyson podcast, along with co-host Sebastian Joseph Day. Rogan was the guest for the episode.

ADVERTISEMENT

Article continues below this ad

In conversation, Tyson was talking about how his doctor advised him to undergo surgery for rotator cuff issues. He also added he was unsure why the doctor advised him to do the same. Tyson said, I feel great. I said I feel great before I got surgery, yall just gotta try to make some money there.

However, he admitted that he could see tears during an MRI scan.

In response, Rogan tells him that he saw his sparring video with Rafael Cordeiro. And, that Tysons shoulder function is the best there is.

In fact, he even asks Tyson to not follow his doctors advice, blatantly stating, Ignore it.

Rogan finally gives Tyson advice on conditioning his mind to ignore the shoulder discomfort. He said, I think its voodoo. I think you got to like keep your mind straight. Just pretend your shoulders dont bother you.

The Baddest Man on the Planet has been a passionate proponent of alternative medicine.

Tyson stated that a psychedelic concoction of the venom from the Sonoran Desert Toad paved a way for his return to boxing.

ADVERTISEMENT

Article continues below this ad

He mentioned he discovered a traditional healing ritual involving the venom. This, in turn, led to Tyson losing 100 pounds and taking up boxing again. He also reconnected with his wife and children.

Talking about his experience, Tyson said, It speaks for itself. If you knew me in 1989 you knew a different person. My mind isnt sophisticated enough to fathom what happened, but life has improved.

ADVERTISEMENT

Article continues below this ad

WATCH THIS STORY Shakur Stevenson vs. Oscar Valdez: Date, Time, Venue, Tickets, and Livestream

What do you think of Rogans statement? Let us know in the comments below.

Continue reading here:

Joe Rogan Tells 55-Year-Old Mike Tyson to Ignore Medical Advice: I think Its Voodoo. You Gotta Keep Your Mind Straight - EssentiallySports

The Indian wellness industry has been witnessing a growth of 12 percent per annum and is predicted to grow rapidly in the upcoming years as the Governments focus on the fitness and health industry has increased recently. The Central Government has been stupendously embracing a holistic approach towards meeting several health challenges and thus emphasizing more on the alternative medicine theories. The Ministry of AYUSH under the Government including Yoga, Unani, Ayurveda, Siddha, and Homeopathy is built to promote Indian traditional healing and wellness procedures that were mostly followed during the Vedic age. One of the finest techniques for wellness, The Panchakarma of Ayurveda has now become the worlds best theory in providing benefits to the preventive healthcare measures and curing chronic disorders.

The Ministry of AYUSH has the objective to upgrade educational standards of the Indian medicinal systems and Homoeopathy colleges along with strengthening the medicinal research institutes and facilitating the time-bound research programs. It also has the aim to develop schemes to promote, cultivate, regenerate medicinal plants, and evolve pharmacopeia standards of the Indian medicines and homeopathy drugs. This has been one of the significant factors for India today to stand as the second-largest exporter of Ayurvedic and herbal products across the world.

Wellness programs and its significance

Promoting wellness in this time is surely an essential task to bring awareness, efficiency and productivity across the country since Covid-19 has showed us the crisis happened with our physical and mental being during the pandemic. Healthy diet, yoga, basic hygiene, and preventive healthcare are essential to stay fit and battle with any kind of diseases. Yoga and Ayurvedic treatments are certainly powerful in mitigating stress and keeping the body and mind aligned from the virus that is making the world fall sick. A holistic wellbeing is significantly necessary to increase the immune system and battle with different health issues. The Government is also set to develop models in which entrepreneurs can choose conventional businesses and grab opportunities offering wellness to Indian citizens as well as citizens from the foreign land.

Challenges to overcome

The Indian wellness industry also has met with several challenges to be addressed. One of those is inadequate infrastructure and a lack of acute shortage of skilled human resources. Also, the estimated cost for the wellness sector in India stands infraction when compared to the world which is around $4.2 trillion. However, it is predicted that by 2030, India has to increase about 2.07 million doctors to the existing count as it is necessary to treat the increasing population. The Government is thus targeting to increase the spending from 1.3 percent to 3 percent of its GDP in 2022. Again, the Government has to increase its funding for the healthcare sector by 20 to 25 percent during the next five years if it wants to achieve sustainable development goals.

To mention here, the government has made remarkable changes during the last few years by revamping the wellness sector by transforming the existing 1.5 lakh sub-health and primary health care centers across India with comprehensive primary health care and a holistic model for wellness. A budget of about Rs. 3,400 crores have also been kept for the next five years for Ayush Wellness Centers under the National Ayush Mission.

Another important aspect is the lack of knowledge about ayurveda in India. Yoga and Ayurvedic courses should be given a strong recognition in the education domain making the generation next aware how it is an integral part of keeping healthy and fit. Introduction and regular practice of Yoga in schools and colleges would enhance the value of taking self-care as well as in promoting the wellness activities around our day-to-day lives.

Additional Initiatives by the Government of India

PM Narendra Modi has taken a big movement by promoting Global AYUSH Investment and Innovation Summit. This move will give a boost to Ayurveda industry for making its global footprints. In 2014, where the AYUSH sector was less than $3 billion, today it has increased to more than $18 billion. Ministry of AYUSH actively fueling startup culture in the field of Traditional Medicines, Ayurvedic products etc. Also, India will soon introduce the AYUSH mark to recognise traditional medicine products which will give the authenticity to quality AYUSH products of the country.

ASSOCHAM has been putting continuous a lot of effort into supporting the Government with several health and wellness initiatives. Several other initiatives are implemented of which in January 2020, IIT Delhi and the All-India Institute of Ayurveda together have signed an MoU for studying the therapeutic benefits of herbal formulations and wellness. About seven collaborations are focusing on different Ayurvedic formulations and practices planned for the next two years. These include examining the effects of six Ayurveda juices on gastrointestinal secretions, developing herbal formulations for reducing harmful effects of reusing cooking oil, developing a biodegradable herbal wound dressing, studying the effects of Brahmari Pranayama on the nervous system, examining the impact of ashes on proteins implicated in neurodegenerative diseases, developing a fumigation device for healing wounds, checking through a device if ayurvedic drugs help in early detection of cancer and offer responses to these drugs in treating breast cancer.

However, India should focus on building more awareness of mental as well as physical health and wellness in collaboration with the Ministry of AYUSH. It should also focus more on start-up India to boost the sector during the next few years.

Views expressed above are the author's own.

END OF ARTICLE

Read the original post:

India as the emerging hub for global wellness and ayurvedic treatment - Times of India

Just because you're no longer in your teen years and awkward puberty stage, doesn't mean you're done with acne. Adult acne is a common problem that can happen in your 30s, 40s and even 50s. but there are ways to help manage it. Eat This, Not That! Health spoke with dermatologists who share their advice for helping get rid of adult acne. Read onand to ensure your health and the health of others, don't miss these Sure Signs You've Already Had COVID.

Dr. Karan Lal of Schweiger Dermatology Group in Hackensack, NJ shares, "Adult onset acne is becoming increasingly common. Some causes include hormonal fluctuations in women, mask use in men and women, taking too many B vitamins(common with B12), hormone supplementation, and increased yeast growth on the skin (more common in those who sweat a lot/ work out)."

Dr. Lilliana Ramrez Garca MD with Nava MD adds, "Hormones play a big role in adult acne. For example, androgens (male hormones that are also present in women) can cause your body to create an excessive amount of sebum. This can clog your pores and causes acne. Chemicals in your hair products, skincare products, makeup, and even your toothpaste can also cause adult acne."

According to Dr. Lal, "Women make up the majority of patients with adult onset acne. Patients with oily/more sebaceous skin are more likely to break out throughout their lives. Patients undergoing transition for gender affirming are also at risk for acne during transition due to hormonal shifts."

Dr. Garcia reveals, "Following a low-glycemic diet (a diet that reduces spikes in blood sugar) can also have a positive impact on acne-prone skin. You see, when your blood sugar spikes, it causes inflammation throughout your body. It can also make your body produce more sebum, or oil. Both inflammation and sebum can cause acne.. To avoid these issues, steer clear of processed foods like white bread, packaged breakfast cereals, and other highly processed foods. Instead, opt for fresh fruits and vegetables, and grains like barley and wild rice, that don't spike your blood sugar."

Dr. Garca says, "Consider a prescription formula containing tretinoin. Tretinoin is a skincare ingredient derived from Vitamin A. It works by speeding up healthy cell turnover, the process of replacing dead skin cells (which can contribute to acne breakouts) with fresh, living cells. It also helps prevent your sebaceous glands from secreting excessive amounts of sebum. Together, these functions make tretinoin effective in preventing and treating acne breakouts. It's also important to mention that tretinoin can stimulate your skin's production of the structural protein, collagen. This can help reduce acne scarring. Nava MD offers personalized prescription solutions containing tretinoin, so it's a great option for women with acne-prone skin."

Dr. Lal shares, "The cure-all for adult acne is Isotretinoin also known as Accutane. This medicine shrinks your oil glands making it inhospitable for bacteria and yeast killing any of your chances of developing pimples. The classic teaching is: If you are over 18 and do a course of Accutane there is an 80% chance you are unlikely to break out in the future. This medicine requires you to see your dermatologist every month. Patients of child bearing potential must also be abstinent or be on two forms of birth control while on treatment due to risk of birth defects."

RELATED: Sure Signs You Have "Bad Breath" Without Knowing It

"There are multiple new devices that are excellent at treating acne," Dr. Lal states. "One of these includes the Neo elite laser by Aerolase which is a painless Nd-Yag laser. This device heats pimples and reduces inflammation. It is safe for ALL skin types and can also treat acne scarring. Treatments need to be done in a series and are not covered by insurance. It's a great alternative for patients who want to avoid pills."6254a4d1642c605c54bf1cab17d50f1e

RELATED: 8 Ways to Make Your "Ugly Feet" More Appealing

Dr. Lal says. "The most common treatments for acne across the board are topical preparations. Medications like tretinoin, benzoyl peroxide, minocycline/clindamycin, when used in combination often result in up to 30-40% improvement in acne. Their efficacy depends on patient consistency and severity of acne. There is a new topical medication called Winlevi which helps address the hormonal component of acne in men and women. It does not cause irritation like some of the other topicals."

Heather Newgen

Read more from the original source:

Acne Cures That Really Work, Says Dermatologist Eat This Not That - Eat This, Not That

The researchers conducted a cross-sectional study to examine the use of complementary and alternative medicine (CAM) from 2019 to 2020.

PUs have many negative consequences, such as pain and disability, extended hospital stay and increased morbidity.

A total of 299 subjects aged 41 to 77 years old, mostly females at 54.2%, with PU from wound clinics and healthcare institutions in Shiraz, Iran, were recruited for the investigation.

The findings were later published in the paper titled The prevalence of using complementary and alternative medicine products among patients with pressure ulcer in the journal BMC Complementary Medicine and Therapies.

Results showed that the most common CAM therapies are: herbal products (100% of participants used this), vitamin supplementation therapy (45.2%), spiritual therapies (21.7%), wet cupping (16.4%), leech therapy (9.4%), acupuncture (1.7%), dry cupping (1.3%) and massage (1.3%).

The most common herbal product used for PU management was Pistacia atlantica gum, either alone or combined with other herbal products (15.5%). Other research noted that the Pistacia atlantica plant, gum and fruit can treat a myriad of disorders in Iran, either topically or orally, and assist in wound healing and pain associated with skin ailments.

All herbal products were applied topically. Other examples include honey, aloe vera, egg albumin and henna.

The most common cause of PU among the subjects is a fracture at 33.78%, while the most common PU site is on the sacrum or buttocks. The most common underlying condition among them was diabetes at 64.2%.

CAM therapies were mainly used to alleviate a chronic disease (71.9%), and only 21.1% of the participants reported the usage of CAM to their physicians.

Another result was that CAM therapies had no significant relationship with the subjects gender, education level, occupation and PU duration.

However, CAM use had a significant relationship with the subjects age, underlying conditions and the PU stage. They retrieved information on CAM from relatives or a simple search online using their mobile phones. This trend was more prevalent among older participants, people with diabetes and stage II PU patients.

Understanding alternative therapy choices

The participants reported that they chose CAM therapies due to the easy accessibility, lower costs and perceived greater effectiveness.

The main reason cited was also to manage chronic conditions, which aligned with other studies in the country.

However, not alerting their physicians would expose the subjects to problems such as drug interactions and medication side effects.

Therefore, quality public education through the mass media is recommended to improve public knowledge about CAM therapies, their uses, and their side effects.

Improving the healthcare provider and laymens knowledge about CAM therapies and the appropriate use of cost-effective CAM therapies in PU management can reduce the need for imported dressings too, which are expensive and not accessible, concluded the researchers.

Source: BMC Complementary Medicine and Therapies

DOI: 10.1186/s12906-022-03573-6

The prevalence of using complementary and alternative medicine products among patients with pressure ulcer.

Authors: Niloofar Karimianfard and Azita Jaberi

Read more from the original source:

Iranians prefer alternative therapies to treat pressure ulcers study - NutraIngredients-Asia

Dynamic Culturing Process Developed by Lineage Offers Path to Clinical- and Industrial-Scale Production of Photoreceptors

CARLSBAD, Calif.--(BUSINESS WIRE)-- Lineage Cell Therapeutics, Inc., (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced a new cell therapy development program: photoreceptor neural cell (PNC) transplants for the treatment of vision loss due to photoreceptor dysfunction or damage. Similar to the companys recently announced pipeline expansion into auditory neurons for the treatment of hearing loss, Lineage has filed for intellectual property protection covering the composition and methods for generating PNCs. Based on recent in vivo data generated using the companys PNCs, these cells may be capable of forming reconstructed retina with high survivability and neural connectivity to surrounding functional layers. Notably, Lineage has demonstrated feasibility which could support a large-scale method for producing both types of photoreceptors, known as rods and cones.

It is natural that, on the heels of the announcement of our alliance with Roche and Genentech for our RPE cell therapy, a deal worth up to $670 million dollars plus double-digit royalties if certain development, approval, and sales milestones are achieved and other conditions are met, that we also would pursue treatments for vision loss through the other major cell type of the retina, the photoreceptors, stated Brian Culley, Lineages CEO. Our fundamental technology and accumulated know-how give us the opportunity to make many different cell types, and we have demonstrated our ability to create new programs rapidly and efficiently in two distinct areas, expanding our cell therapy pipeline to five separate preclinical and clinical programs, while still maintaining what we believe is an appropriate and responsible rate of investment for a company of our size. This latest program is part of our long-term planning for clinical and commercial success and serves as another example of the capability of our technology platform. We believe our ability to, in just a matter of months, advance from a product concept to generating new intellectual property and manufacturing the desired cell types, is illustrative of the power and efficiency of our platform. We believe the combination of our capital discipline and current balance sheet will support multiple years of further progress, during which we anticipate reaching achievements with each of our clinical and preclinical programs.

Dr. Rami Skaliter, who leads the manufacturing function for Lineage, added, Im exceptionally proud of the teams success at overcoming obstacles related to the limited scale of photoreceptor production. Building upon our experience with other cell lineages, we have developed intellectual property, and filed for patent protections, on a manufacturing process which is compatible with large-scale production of photoreceptors in a closed system, improvements which could enable industrial manufacturing. We believe this accomplishment will provide new opportunities for clinical, and ultimately commercial, production of photoreceptors in areas of large unmet need such as Retinitis Pigmentosa, Stargardts Macular Dystrophy, and retinal detachments, either independently or through strategic alliances.

As part of a scientific collaboration with Professors Benjamin Reubinoff, M.D., Ph.D. and Eyal Banin, M.D., Ph.D., of the Hadassah-Hebrew University Medical Center, the differentiation of pluripotent cells into photoreceptors with clinically compatible characteristics was established utilizing a novel differentiation protocol which generated positive identity of key markers of both rods and cones photoreceptor populations. The data generated by the company further demonstrated that a single cell suspension of photoreceptor precursor cells has the potential to survive and mature post-transplantation in a rodent model of retinal degeneration.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineages programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineages clinical programs are in markets with billion dollar opportunities and include five allogeneic (off-the-shelf) product candidates: (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, which is now being developed under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineages VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy, and (v) PNC1, a photoreceptor neural cell therapy for the treatment of vision loss due to photoreceptor dysfunction or damage. For more information, please visit http://www.lineagecell.com or follow the company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as believe, aim, may, will, estimate, continue, anticipate, design, intend, expect, could, can, plan, potential, predict, seek, should, would, contemplate, project, target, tend to, or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to (i) the potential amount of payments to Lineage under the alliance with Hoffman-La Roche Ltd. (Roche) and Genentech, Inc., (ii) the potential for new opportunities for clinical, and ultimately commercial, production of photoreceptors in areas of large unmet need, (iii) Lineages position to become a leader in the emerging field of regenerative medicine and anti-aging technology, and (iv) future areas of potential treatment using PNC transplant. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineages actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, but not limited to, the risk that competing alternative therapies may adversely impact the commercial potential of OpRegen, which could materially adversely affect the payments payable to Lineage under the Roche/Genentech collaboration and license agreement, the risk that Roche/Genentech may not be successful in completing further clinical trials for OpRegen and/or obtaining regulatory approval for OpRegen in any particular jurisdiction; the risk that Lineage might not succeed in developing products and technologies that are useful in medicine and demonstrate the requisite safety and efficacy to achieve regulatory approval in accordance with its projected timing, or at all; the risk that Lineages intellectual property may be insufficient to protect its assets; risks and uncertainties inherent in Lineages business and other risks discussed in Lineages filings with the Securities and Exchange Commission (SEC). Lineages forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading Risk Factors in Lineages periodic reports with the SEC, including Lineages most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the SEC and its other reports, which are available from the SECs website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005336/en/

See more here:

Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness -...

Dr. Freeman: "Mr. Vargas, great news on the biopsy results: all negative. It means the workup we have done, including imaging, blood work, and endoscopies, is all normal. Youre all set."

Mr. Vargas: "How can that be? I feel miserable!"

The clinical scenario above (names altered for privacy) is surprisingly common for gastroenterologists. These doctors of the esophagus, stomach, small intestines, colon, pancreas, and liver are well trained to identify and treat conditions of the gastrointestinal (GI) tract that occur from diseases caused by inflammation, infection, or cancer.

While some of these conditions can be devastating, they are usually easy to diagnose on standard testing. But there are other illnesses that can impact the GI tract that do not have a clear laboratory test or finding on endoscopy to identify them. One such class of these is called disorders of gut-brain interaction, or DGBIs. Some people (including doctors) may be familiar with the older term used to describe these conditions functional GI diseases but it is no longer used.

DGBIs can include irritable bowel syndrome, reflux hypersensitivity, or functional dyspepsia. They are called disorders of gut-brain interaction because it is believed the most critical abnormality is impaired communication between the gut and the brain via the nervous system in both directions (from gut to brain and brain to gut).

Some things are associated with the development of DGBIs, including having suffered from prior infections, particularly those that have symptoms like nausea or diarrhea. DGBIs are more prevalent in certain populations, including women. Depression and anxiety are independent illnesses that can be associated with DGBIs as well. Unfortunately, the mechanisms of why DGBIs happen are still not well defined, which can be frustrating for patients and their providers.

From the perspective of specialists like me, DGBI management is not given a lot of attention in clinical training. This can lead to unnecessary testing that has risks, including perforation from endoscopy or radiation from imaging. Even more confusing is that DGBIs can overlap with other GI diseases. As an example, functional dyspepsia (a type of chronic indigestion) can overlap with gastroparesis (slow stomach emptying). Irritable bowel syndrome can overlap with inflammatory bowel diseases (like ulcerative colitis and Crohns disease).

DGBIs can be treated with multiple primary approaches, and these can also be combined: lifestyle, including dietary approaches; medications; complementary/alternative medicine approaches; and behavioral therapy. Lifestyle and complementary and alternative medicine approaches can be attractive options for some patients.

While eliminating very fatty and processed foods may improve GI symptoms when you have a DGBI, it is hard to sustain such severe changes in diet to control symptoms, and when done too strictly can lead to other conditions, such as feeding difficulties from avoidant restrictive food intake disorder.

Some people might try a low-FODMAP diet (this should be avoided if youve had an eating disorder). You can try to avoid FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols)-containing foods for one month (ideally guided by a doctor and/or a dietitian), and completely return to a normal diet if there is no improvement. If there is improvement, then add back foods systematically to make sure your diet is varied and provides all necessary nutrients.

Sometimes people consider acupuncture, ginger, turmeric, or herbal supplements, which you should always discuss with your doctor to prevent side effects or serious health issues, including liver problems.

Medication-based approaches typically use medications that have been used to treat conditions like depression, neuropathy, and fibromyalgia. Sometimes doctors do not clearly explain the rationale for using such medications; however, they are meant to improve the gut-brain interaction by improving pain sensation pathways in the brain, and perhaps even stimulating improved nerve function.

Finally, GI-directed behavioral therapies use cognitive behavioral approaches to improve GI symptom-specific anxiety with the help of a psychologist or therapist.

If your doctor has identified that you have a DGBI, make sure to emphasize how much it is negatively impacting your quality of life. For a condition like irritable bowel syndrome, the change in bowel movements and the associated pain can really cause daily distress. Many DGBIs can affect your ability to do certain types of work that may not allow you easy access to a bathroom. DGBIs also affect sexual health.

Make sure your provider understands that managing your DGBI is important, and you want to work together to find the right treatment approaches (or a combination of approaches), as discussed above.

Beyond this, it is important to recognize that DGBIs are established diagnoses, and are just as valid as any other gastrointestinal disease. When you have symptoms of a DGBI, it is not because of an issue of willpower or weakness, or " just in your head." These are disorders for which good treatments exist, and they can improve your symptoms and quality of life.

As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.

See the original post:

Recognizing and treating disorders of gut-brain interaction - Harvard Health